Labetuzumab govitecan  (Synonyms: IMMU 130; hMN-14-SN-38)

Labetuzumab govitecan (IMMU 130) is an Anti-CEACAM5/SN-38 antibody-drug conjugate (ADC). Labetuzumab govitecan consists of the antibody Labetuzumab, SN-38, and a pH-sensitive Linker. Labetuzumab govitecan can be used for research of cancers, such as colorectal cancer^[1][2][3].

Labetuzumab govitecan (total of 1.0 mg, i.p.) prolongs median survival of GW-39 lung metastatic mouse model^[2].
Labetuzumab govitecan (25 mg/kg, i.p., twice weekly for 4 weeks) prolongs median survival of sc LS174T Xenograft in nude mice^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

154000 (average)

1469876-18-3

Liquid

Colorless to light yellow

[Labetuzumab govitecan]

Shipping with dry ice.

-80°C, protect from light

• [1]. Dotan E, et al. Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer. J Clin Oncol. 2017 Oct 10;35(29):3338-3346.  [Content Brief]

  [2]. Govindan SV, et al. Improving the therapeutic index in cancer therapy by using antibody-drug conjugates designed with a moderately cytotoxic drug. Mol Pharm. 2015 Jun 1;12(6):1836-47.  [Content Brief]

  [3]. Criscitiello C,et al. Antibody-drug conjugates in solid tumors: a look into novel targets. J Hematol Oncol. 2021 Jan 28;14(1):20.  [Content Brief]